Philadelphia chromosome-positive acute myeloid leukemia (Ph + -AML) has a poor response to anthracycline-and cytarabine-containing regimens, high relapse rate, and dismal prognosis. Although therapy with imatinib and allogeneic stem cell transplantation (allo-SCT) is promising, relatively short follow-up limits understanding of long-term results of these therapies. This report describes the outcomes of 3 cases of Ph +
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Learning Objectives
Upon completion of this activity, participants will be able to:
• Describe the rationale for the use of imatinib in the treatment of patients with Ph + -AML 
Case Report
The details of each patient are described in Tables 1  and 2 . All patients, young and without comorbidities, presented with acute to subacute symptoms. The third patient had a history of stage IB right breast cancer diagnosed 3 years before presentation, which was treated with mastectomy, sentinel lymph node dissection, and adjuvant cyclophosphamide and doxorubicin (4 cycles); the patient subsequently underwent maintenance therapy with oral tamoxifen. All 3 patients had splenomegaly. The WBC count at presentation was 143,000/µL (66% blasts; 5% basophils) in the first patient ( Figure 1) ; 159,000/µL (36% blasts; 0%-2% basophils) in the second patient; and 96,900/µL (12% blasts; 1% basophils) in the third patient. Bone marrow aspirate and biopsy revealed increased myeloblasts (>20%) in all patients; additionally the first patient had increased basophils ( Figure 2 ). Immunophenotyping confirmed myeloid lineage and ruled out biphenotypic acute leukemia. 8 Conventional cytogenetics and fluorescence in situ hybridization (FISH) studies detected a t(9;22)(q34;q11.2), consistent with the Ph chromosome, in the first and the second patients ( Figure 3A ). In addition, studies detected a subclone further characterized by a t(14;17)(q32;q24) in the first patient, which was confirmed by FISH to include disruption of the IGH locus at 14q32 ( Figure 3B ). FISH showed the presence of BCR-ABL in 17 of 17 cells in the third patient; however, a lack of mitotic cells prohibited conventional cytogenetic analysis. All of the patients received induction therapy with 7 days of cytarabine and 3 days of idarubicin along with imatinib, and consolidation therapy with high-dose cytarabine (± imatinib). The first and the third patients did not receive imatinib during consolidation because of grade 3 hepatotoxicity and grade 3 diarrhea, respectively. The cytogenetic abnormalities had resolved at the time of allo-SCT in the first and the third patients, but persisted in Philadelphia chromosome-positive acute myeloid leukemia (Ph + -AML) is rare, accounting for approximately 1% of all cases of AML.
1-3 Whether Ph + -AML is distinct from the blast phase of chronic myeloid leukemia (CML) was controversial until recently. A 2013 study showed that NPM1 mutations are seen exclusively in Ph + -AMLs (22%; n=9) whereas ABL1 mutations are exclusive to the blast phase of CML (20%; n=5), suggesting that Ph + -AML is distinct from blast phase CML. These mutational analyses can be helpful in clinical practice or research trials to distinguish between the entities. 4 Clinical characteristics might also be helpful in making the distinction, including no history of CML or myeloproliferative disorder, no evidence of chronic or accelerated phases of CML after induction therapy, and no characteristics of CML, such as splenomegaly and basophilia. In addition, compared with the blast phase of CML, Ph + -AML is associated with very high leukocytosis, the p210 BCR-ABL protein (vs p190 BCR-ABL protein), and the coexistence of normal metaphases in addition to Ph + metaphases. 5 The presence of dwarf megakaryocytes in bone marrow 4 ; additional cytogenetic aberrations, such as an extra copy of Ph chromosome, trisomies 8 and 19, and isochromosome 17q; and the persistence of t(9;22) after induction therapy are more common in the blast phase of CML than in Ph + -AML. 5 None of these features, however, are diagnostic of blast-phase CML or Ph + -AML.
The presence of the Ph chromosome in acute lymphoblastic leukemia is a poor prognostic factor leading to the recommendation of allogeneic stem cell transplantation (allo-SCT) whenever possible, 6 but its prognostic significance and the optimal treatment of Ph + -AML are not clear. With the current treatment options, the outcome is dismal (with a median overall survival of 9 months in one study).
1
Although several therapy options are promising, including imatinib and allo-SCT, relatively short follow-up limits understanding of long-term results of these therapies. 7 This report describes the outcomes of 3 cases of Ph + -AML diagnosed and transplanted at the University of Nebraska Medical Center between 2004 and 2011. Despite the lack of consensus on accurate case definition, the lack of prior history of CML or myeloproliferative disorder, and the absence of the evidence of chronic or accelerated phases of CML after induction therapy seem to be the most important diagnostic criteria for Ph + -AML and were [7] 46,XX [20] Type/timing of SCT the second patient. All of the patients underwent 10/10 HLA-matched allo-SCT (sibling donor for the first and the third patients and unrelated donor for the second patient). In all cases, peripheral blood progenitor cells were the graft source. In the first and second patients, cyclophosphamide (60 mg/ kg/d for 2 days) and total body irradiation (200 cGy twice daily for 3 days) were used as the conditioning regimen, whereas the third patient received busulfan (3.2 mg/kg/d for 4 days) and fludarabine (30 mg/m 2 /d for 5 days). For graft-versus-host disease (GVHD) prophylaxis, the first and the third patients received tacrolimus and mycophenolate mofetil, whereas the second patient received tacrolimus and methotrexate. All the patients had acute GVHD (grade 2 skin, grade 1 gut, and grade 1 skin in the first, second, and third patients, respectively). The first (limited disease) and third (extensive disease) patients also had chronic GVHD. All patients are currently alive and experiencing complete remission at 116, 113, and 28 months after diagnosis, respectively.
Discussion
The t(9;22)(q34;q11.2) translocation, which results in the Ph chromosome, can occur in AML as a de novo chromosomal aberration with or without additional abnormalities or as a therapyrelated event.
2, 9 In de novo cases, it may be present at AML diagnosis or relapse. 1, 10, 11 In the present report, the first and the second patients had de novo chromosomal aberrations, whereas the third patient had therapy-related Ph + -AML. The occurrence of the Ph chromosome in AML with core-binding factor leukemia or with certain genetic aberrations, such as NPM1 mutations, may indicate a role as a cooperating mutation that enhances cell proliferation (class I mutation). 10 Ph + -AMLs display varying degrees of maturation, are classifiable into different FrenchAmerican-British types, frequently express lymphoid markers, and demonstrate clonal rearrangement of the immunoglobulin or T-cell receptor genes. 3 The few publications available on the treatment and outcome of patients with Ph + -AML suggest a poor response to anthracycline-and cytarabinecontaining regimens, 2 high relapse rate, and dismal prognosis. 1 Although a transient response with imatinib alone (n=2) and with chemotherapy (n=5) have been reported, 1 several case reports have shown good responses to imatinib as a first-line therapy (initial dose, 400 mg/d) 12 and as a salvage therapy after chemotherapy failure (initial dose, 600 mg/d). 13, 14 Use of imatinib for postremission maintenance therapy after induction chemotherapy has resulted in complete remissions lasting for 10 to 19 months. 15, 16 In one instance, combination leukemia-type chemotherapy and imatinib after failure of induction therapy with single-agent imatinib resulted in a complete cytogenetic response. Consolidation chemotherapy and imatinib followed by postremission imatinib led to a complete molecular response, which continued 15 months from diagnosis. 17 Taken together, these results indicate that imatinib can play a valuable role in postremission therapy, even when Ph + -AML is resistant to first-line single-agent imatinib.
Ph + -AML with additional abnormalities, rather than Ph + -AML alone, may behave differently. Ph + - BCR-ABL fusion was detected by fluorescence in situ hybridization. Results were considered positive if ≥2% of interphase cells exhibited the dual fusion BCR-ABL signal pattern. The quantitative real-time reverse transcriptase polymerase chain reaction/DNA amplification assay used for BCR-ABL fusion transcript was able to detect the p210 fusion transcript (derived from b2a2 or b3a2 translocation) and the p190 fusion transcript (derived from the e1a2 translocation). The test result was negative after stem cell transplantation and at last follow-up in the first and second patients. In the third patient, the test showed 95% p210 BCR-ABL (b3a2 translocation) in peripheral blood at diagnosis, which decreased to < 0.01% after induction. Immediately after transplant, there was sporadic p190 BCR-ABL1 (e1a2) but no p210. Subsequent tests, including the one at last follow-up, have been negative. In the third patient, no FLT3 and JAK2 V617F mutation was seen in the bone marrow specimen at diagnosis. AML with monosomy 7 is considered to be a worse risk and is associated with poor response to therapy and short duration of remission. 18 Conversely, the presence of favorable-risk cytogenetics may be associated with better outcomes. Two cases of Ph + -AML in association with inv(16) had excellent outcomes with chemotherapy (alive in remission 3 years after diagnosis) and allo-SCT (alive in complete remission 18 months post-SCT), respectively. 19 Similarly, allo-SCT and chemotherapy with or without imatinib resulted in complete remission at 22 and 70 months after diagnosis in 2 patients with Ph + -AML with t(8;21). 10 A patient with acute promyelocytic leukemia with a Ph chromosome experienced complete remission with all-trans retinoic acid and chemotherapy for 4 years from diagnosis. 20 Additionally, the presence of a Ph chromosome in patients with otherwise good-risk AML may 21 indicate a poor prognosis. 10 Only a few instances of allo-SCT have been reported in Ph + -AML. In one study, allo-SCT (n=7) resulted in a median overall survival of 12 months 1 (patients' characteristics are not available). In another study, 4 men (age, 18-44 years) were treated with AML-type induction chemotherapy, with further augmentation chemotherapy in 3 patients, followed by imatinib and consolidation chemotherapy. Two patients experienced molecular remission, whereas the other 2 experienced complete hematologic remission. Subsequently, these patients received a cyclophosphamide (120 mg/kg) and total body irradiation (1320 cGy) preparative regimen, and sibling (n=2) or unrelated (n=2) peripheral (n=1) or bone marrow (n=3) allo-SCT. Two patients had acute GVHD and 3 had chronic GVHD, whereas 1 did not have either acute or chronic GVHD. At 6 to 24 months' follow-up, all of the patients were alive in molecular remission; however, the long-term outcome was not reported. 7 The present report shows that allo-SCT can result in long-term remission and possible cure in some patients with Ph + -AML. The second patient had experienced morphologic complete remission but not cytogenetic remission at the time of allo-SCT, thus suggesting that allo-SCT can achieve cure even in such a setting. In addition to the overall advancement in the techniques of allo-SCT and supportive care, the young age, absence of comorbidities and additional high-risk cytogenetics, incorporation of imatinib, and occurrence of GVHD (suggesting graft-versus-leukemia effect) in the present patients may have contributed to the excellent outcomes. Although the benefit of consolidation with high-dose cytarabine with or without imatinib before allo-SCT is unclear, this should at minimum be considered as an interim therapy while awaiting allo-SCT. The NCCN Clinical Practice Guidelines in Oncology for AML recommend treating Ph + -AML as myeloid blast-phase CML with tyrosine kinase inhibitor (alone or in combination with AML-type induction chemotherapy) followed by hematopoietic SCT, if feasible, or enrollment in a clinical trial (available at NCCN.org). 22, 23 In conclusion, Ph + -AML is a rare condition that is incompletely studied. Available reports, including this one, suggest that long-term remission is possible. The use of allo-SCT, with resultant graft-versusleukemia effect, and the addition of imatinib provide potentially curative properties. 
